(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 6.15% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Bio Techne's revenue in 2026 is $1,210,811,000.On average, 18 Wall Street analysts forecast TECH's revenue for 2026 to be $195,710,938,750, with the lowest TECH revenue forecast at $186,786,519,943, and the highest TECH revenue forecast at $204,165,651,304. On average, 17 Wall Street analysts forecast TECH's revenue for 2027 to be $208,236,438,830, with the lowest TECH revenue forecast at $196,024,076,252, and the highest TECH revenue forecast at $217,943,701,392.
In 2028, TECH is forecast to generate $228,590,376,460 in revenue, with the lowest revenue forecast at $211,524,382,601 and the highest revenue forecast at $254,893,926,628.